Which has higher valuation & earnings, PEN or ZBH?

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.95 $177.69M $4.07 78.40 Zimmer Biomet $8.51B 2.04 $705.20M $4.11 22.16

Is PEN or ZBH more profitable?

Penumbra has a net margin of 10.67% compared to Zimmer Biomet's net margin of 9.48%. Zimmer Biomet's return on equity of 13.12% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% Zimmer Biomet 9.48% 13.12% 7.23%

Does the media prefer PEN or ZBH?

In the previous week, Zimmer Biomet had 5 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Zimmer Biomet and 2 mentions for Penumbra. Zimmer Biomet's average media sentiment score of 0.76 beat Penumbra's score of 0.62 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBH or BSX?

In the previous week, Zimmer Biomet had 1 more articles in the media than Boston Scientific. MarketBeat recorded 7 mentions for Zimmer Biomet and 6 mentions for Boston Scientific. Zimmer Biomet's average media sentiment score of 0.76 beat Boston Scientific's score of 0.57 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Boston Scientific 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBH or EW?

In the previous week, Zimmer Biomet and Zimmer Biomet both had 7 articles in the media. Zimmer Biomet's average media sentiment score of 0.76 beat Edwards Lifesciences' score of 0.39 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edwards Lifesciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ZBH or BDX?

In the previous week, Becton, Dickinson and Company had 2 more articles in the media than Zimmer Biomet. MarketBeat recorded 9 mentions for Becton, Dickinson and Company and 7 mentions for Zimmer Biomet. Becton, Dickinson and Company's average media sentiment score of 0.85 beat Zimmer Biomet's score of 0.76 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IDXX or ZBH?

In the previous week, Zimmer Biomet had 2 more articles in the media than IDEXX Laboratories. MarketBeat recorded 7 mentions for Zimmer Biomet and 5 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.16 beat Zimmer Biomet's score of 0.76 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zimmer Biomet (ZBH) Competitors

$91.08 +1.39 (+1.55%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$91.18 +0.10 (+0.11%)

As of 09/25/2026 07:45 PM Eastern

Compare

ZBH vs. PEN, BSX, EW, BDX, and IDXX

Should you buy Zimmer Biomet stock or one of its competitors? Zimmer Biomet's main competitors and comparable companies include Penumbra (PEN), Boston Scientific (BSX), Edwards Lifesciences (EW), Becton, Dickinson and Company (BDX), and IDEXX Laboratories (IDXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Zimmer Biomet compare to Penumbra?

Penumbra (NYSE:PEN) and Zimmer Biomet (NYSE:ZBH) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

88.9% of Penumbra shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Penumbra currently has a consensus target price of $367.07, suggesting a potential upside of 15.04%. Zimmer Biomet has a consensus target price of $103.00, suggesting a potential upside of 13.08%. Given Penumbra's higher possible upside, research analysts clearly believe Penumbra is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.18

In the previous week, Zimmer Biomet had 5 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Zimmer Biomet and 2 mentions for Penumbra. Zimmer Biomet's average media sentiment score of 0.76 beat Penumbra's score of 0.62 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.95	$177.69M	$4.07	78.40
Zimmer Biomet	$8.51B	2.04	$705.20M	$4.11	22.16

Penumbra has a net margin of 10.67% compared to Zimmer Biomet's net margin of 9.48%. Zimmer Biomet's return on equity of 13.12% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
Zimmer Biomet	9.48%	13.12%	7.23%

Summary

Zimmer Biomet beats Penumbra on 9 of the 16 factors compared between the two stocks.

How does Zimmer Biomet compare to Boston Scientific?

Zimmer Biomet (NYSE:ZBH) and Boston Scientific (NYSE:BSX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

In the previous week, Zimmer Biomet had 1 more articles in the media than Boston Scientific. MarketBeat recorded 7 mentions for Zimmer Biomet and 6 mentions for Boston Scientific. Zimmer Biomet's average media sentiment score of 0.76 beat Boston Scientific's score of 0.57 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Boston Scientific	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Boston Scientific has a net margin of 17.50% compared to Zimmer Biomet's net margin of 9.48%. Boston Scientific's return on equity of 19.28% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
Boston Scientific	17.50%	19.28%	10.89%

Boston Scientific has higher revenue and earnings than Zimmer Biomet. Boston Scientific is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.51B	2.04	$705.20M	$4.11	22.16
Boston Scientific	$21.00B	3.03	$2.90B	$2.47	17.77

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.3% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Zimmer Biomet presently has a consensus target price of $103.00, indicating a potential upside of 13.08%. Boston Scientific has a consensus target price of $70.19, indicating a potential upside of 59.96%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.18
Boston Scientific	2 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.68

Zimmer Biomet has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Summary

Boston Scientific beats Zimmer Biomet on 11 of the 16 factors compared between the two stocks.

How does Zimmer Biomet compare to Edwards Lifesciences?

Zimmer Biomet (NYSE:ZBH) and Edwards Lifesciences (NYSE:EW) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Zimmer Biomet currently has a consensus price target of $103.00, indicating a potential upside of 13.08%. Edwards Lifesciences has a consensus price target of $100.27, indicating a potential upside of 16.06%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.18
Edwards Lifesciences	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.74

Edwards Lifesciences has a net margin of 15.43% compared to Zimmer Biomet's net margin of 9.48%. Edwards Lifesciences' return on equity of 15.68% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
Edwards Lifesciences	15.43%	15.68%	12.05%

In the previous week, Zimmer Biomet and Zimmer Biomet both had 7 articles in the media. Zimmer Biomet's average media sentiment score of 0.76 beat Edwards Lifesciences' score of 0.39 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zimmer Biomet has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Edwards Lifesciences has lower revenue, but higher earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.51B	2.04	$705.20M	$4.11	22.16
Edwards Lifesciences	$6.07B	8.20	$1.07B	$1.74	49.65

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Edwards Lifesciences beats Zimmer Biomet on 10 of the 15 factors compared between the two stocks.

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Zimmer Biomet (NYSE:ZBH) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Zimmer Biomet has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Zimmer Biomet has a net margin of 9.48% compared to Becton, Dickinson and Company's net margin of 4.52%. Becton, Dickinson and Company's return on equity of 14.79% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
Becton, Dickinson and Company	4.52%	14.79%	6.93%

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zimmer Biomet presently has a consensus target price of $103.00, indicating a potential upside of 13.08%. Becton, Dickinson and Company has a consensus target price of $187.67, indicating a potential upside of 2.27%. Given Zimmer Biomet's higher probable upside, research analysts clearly believe Zimmer Biomet is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.18
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.1%. Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.3%. Zimmer Biomet pays out 23.4% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 126.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Becton, Dickinson and Company has raised its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Becton, Dickinson and Company has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.51B	2.04	$705.20M	$4.11	22.16
Becton, Dickinson and Company	$21.84B	2.32	$1.68B	$3.32	55.27

In the previous week, Becton, Dickinson and Company had 2 more articles in the media than Zimmer Biomet. MarketBeat recorded 9 mentions for Becton, Dickinson and Company and 7 mentions for Zimmer Biomet. Becton, Dickinson and Company's average media sentiment score of 0.85 beat Zimmer Biomet's score of 0.76 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Becton, Dickinson and Company beats Zimmer Biomet on 11 of the 19 factors compared between the two stocks.

How does Zimmer Biomet compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Zimmer Biomet (NYSE:ZBH) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Zimmer Biomet had 2 more articles in the media than IDEXX Laboratories. MarketBeat recorded 7 mentions for Zimmer Biomet and 5 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.16 beat Zimmer Biomet's score of 0.76 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEXX Laboratories has higher earnings, but lower revenue than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	9.51	$1.06B	$14.22	36.52
Zimmer Biomet	$8.51B	2.04	$705.20M	$4.11	22.16

IDEXX Laboratories currently has a consensus target price of $747.00, suggesting a potential upside of 43.86%. Zimmer Biomet has a consensus target price of $103.00, suggesting a potential upside of 13.08%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, equities analysts clearly believe IDEXX Laboratories is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.18

IDEXX Laboratories has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

IDEXX Laboratories has a net margin of 25.03% compared to Zimmer Biomet's net margin of 9.48%. IDEXX Laboratories' return on equity of 71.96% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
Zimmer Biomet	9.48%	13.12%	7.23%

Summary

IDEXX Laboratories beats Zimmer Biomet on 11 of the 15 factors compared between the two stocks.

Get Zimmer Biomet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBH vs. The Competition

Export

Metric	Zimmer Biomet	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$17.36B	$5.54B	$7.29B	$22.90B
Dividend Yield	1.07%	1.80%	2.52%	3.68%
P/E Ratio	22.16	25.31	275.84	28.00
Price / Sales	2.04	44.44	614.77	20.51
Price / Cash	6.53	32.96	79.23	41.86
Price / Book	1.42	5.77	10.44	4.66
Net Income	$705.20M	$151.55M	$3.51B	$1.07B
7 Day Performance	-4.55%	-0.97%	-1.31%	-1.12%
1 Month Performance	-10.18%	-4.82%	-4.72%	-5.14%
1 Year Performance	-7.22%	7.60%	14.96%	7.69%

Zimmer Biomet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBH Zimmer Biomet	4.0353 of 5 stars	$91.08 +1.6%	$103.00 +13.1%	-6.0%	$17.36B	$8.51B	22.16	17,000
PEN Penumbra	2.8125 of 5 stars	$318.66 +0.3%	$367.07 +15.2%	+27.9%	$12.51B	$1.50B	78.29	4,700
BSX Boston Scientific	4.6765 of 5 stars	$43.71 +0.9%	$70.27 +60.8%	-55.2%	$62.81B	$20.07B	17.70	59,000	Analyst Forecast
EW Edwards Lifesciences	3.5789 of 5 stars	$88.22 0.0%	$100.27 +13.7%	+14.7%	$50.82B	$6.07B	50.70	16,000	Analyst Downgrade
BDX Becton, Dickinson and Company	3.0624 of 5 stars	$180.60 -0.2%	$187.67 +3.9%	+1.5%	$49.86B	$21.84B	54.40	72,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZBH) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, BSX, EW, BDX, and IDXX

How does Zimmer Biomet compare to Penumbra?

Summary

How does Zimmer Biomet compare to Boston Scientific?

Summary

How does Zimmer Biomet compare to Edwards Lifesciences?

Summary

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Summary

How does Zimmer Biomet compare to IDEXX Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, BSX, EW, BDX, and IDXX

How does Zimmer Biomet compare to Penumbra?

Do insiders and institutionals hold more shares of PEN or ZBH?

Do analysts recommend PEN or ZBH?

Does the media prefer PEN or ZBH?

Which has more volatility & risk, PEN or ZBH?

Which has higher valuation & earnings, PEN or ZBH?

Is PEN or ZBH more profitable?

Summary

How does Zimmer Biomet compare to Boston Scientific?

Does the media favor ZBH or BSX?

Is ZBH or BSX more profitable?

Which has better earnings and valuation, ZBH or BSX?

Do institutionals and insiders believe in ZBH or BSX?

Do analysts rate ZBH or BSX?

Which has more volatility & risk, ZBH or BSX?

Summary

How does Zimmer Biomet compare to Edwards Lifesciences?

Do analysts rate ZBH or EW?

Is ZBH or EW more profitable?

Does the media favor ZBH or EW?

Which has more volatility and risk, ZBH or EW?

Which has higher valuation and earnings, ZBH or EW?

Do institutionals & insiders believe in ZBH or EW?

Summary

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Which has more risk & volatility, ZBH or BDX?

Is ZBH or BDX more profitable?

Do insiders & institutionals have more ownership in ZBH or BDX?

Do analysts rate ZBH or BDX?

Is ZBH or BDX a better dividend stock?

Which has higher valuation & earnings, ZBH or BDX?

Does the media prefer ZBH or BDX?

Summary

How does Zimmer Biomet compare to IDEXX Laboratories?

Do institutionals & insiders hold more shares of IDXX or ZBH?

Does the media refer more to IDXX or ZBH?

Which has higher earnings and valuation, IDXX or ZBH?

Do analysts prefer IDXX or ZBH?

Which has more risk & volatility, IDXX or ZBH?

Is IDXX or ZBH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools